Ion Exchange India Ltd

Covered by Minerva Capital Research SolutionsNSE: IONEXCHANGBSE: 500214
Compare with peers
₹ 342.35▼ 1.15 (−0.33%)28 Oct, 03:29 pm IST
P/E
45.7x
52-week range
312.7 – 486
ROE
12%
ROCE
14%
Sector
Other Utilities
Industry
Water Supply & Management
Listed on
NSE, BSE

Quick check

The five things to look at first. Open one for more.

Ion Exchange India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)45.7 against a typical 20.4: pricier than most peers (1st = cheapest).8th of 9
  • Sales growth+20.1% against a typical +20.8% from a year earlier.5th of 6
  • Profit growth−93.7% against a typical +7.1% from a year earlier.5th of 5
  • Share price, 3 months−19.2% against a typical −21.2%.4th of 8

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Adequate safety

Rated A+ by CRISIL
A+
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
CRISILCrisil A+Stable20 Mar 2026
Credit rating actions
RatingDetails
20 Mar 2026
Reaffirmed
Crisil A+—CRISIL₹ 2,099.74 Cr.
17 Mar 2026
Reaffirmed
Crisil A+—CRISIL₹ 2,099.74 Cr.

Research by Minerva Capital Research Solutions

Our research team's work on Ion Exchange India Ltd

In our sector reports

Sector note · 11 Feb 2025 · Free
Our view
Unrated
Price then
INR 532.95/-
Market cap then
INR 7,816.60 Cr.

Ion Exchange offers water-cycle solutions across engineering projects, chemicals and consumer products, with facilities in India and overseas. Engineering projects had an order book of INR 3,405 Cr. in Dec’24.

Profile Highlights

  • Engineering projects: The segment’s bid pipeline was INR 8,648 Cr., with an estimated ~15% conversion ratio.
  • Chemicals expansion: The chemicals segment recorded sales of INR 596 Cr. in 9M-FY25. Roha plant capacity expansion was expected to commence operations by Q2FY26.

Key Risks

  • Order execution and margins: The report attributes lower engineering EBIT margins to execution of a lumpy, lower-margin order, and notes delays on some orders linked to state funding constraints.
  • Consumer products and working capital: The consumer products segment had yet to turn EBIT positive; working-capital intensity and off-balance-sheet bank guarantees are also flagged.

Standard disclosures

  • Research Analyst has served as an officer, director or employee of subject company(ies): No
  • We or our associates have received compensation from the subject company(ies) in the past 12 months: No
  • We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
  • We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
  • We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
  • We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
  • Nature of financial interest in subject company, if any –Nil
  • We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
  • Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No.
  • We or our Associates or Research Analyst are engaged in market making of subject company – No
  • By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
  • There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

Regulatory disclosures

Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).

Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.

The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.

For any queries or grievances: Mr. Nishant Gupta | Email: guptanishant.iimi@gmail.com | Contact Number: 8171433387 | Website: www.mcapital.in

Rating rationale

Minerva Capital Research Solutions endeavors to provide objective opinions and recommendations. Ratings are assigned to stocks according to their fair value vs current market price and then categorizes them as Buy, Hold, Reduce, Sell. The performance horizon is one year unless specified and fair value is defined as analyst’s valuation for a stock.

  • Buy:> 15%
  • Hold: -5% to 15%
  • Reduce: -15% to -5%
  • Sell: <-15%

Board meetings

Results dates and other board meetings. Full calendar

Details
5 Aug 2026Financial ResultsTo consider and approve the unaudited financial results for the first quarter ended June 30, 2026
26 May 2026Financial Results/DividendTo consider and approve the Audited Financial Results and recommend dividend, if any, for the financial year ended March 31, 2026
29 Jan 2026Financial ResultsION EXCHANGE (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 29th January, 2026 to inter-alia, consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December, 2025
4 Nov 2025Financial ResultsTo consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2025
30 Jul 2025Financial ResultsTo consider and approve the unaudited financial results for the quarter ended June 30, 2025
28 May 2025Financial Results/DividendTo consider and approve the financial results for the period ended March 31, 2025 and dividend, if any.

Share price

1Y change −13.84%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales533554782568644691835583734734863700
Expenses473483690503576615749521665675844669
Operating Profit607192646875866368592032
OPM %11.3%12.7%11.8%11.3%10.6%10.9%10.3%10.7%9.3%8.1%2.3%4.5%
Other Income1191711159151815−4436
Interest4333434338119
Depreciation91010101111121212192022
Profit before tax59679562687085666829327
Tax %28.2%29.7%23.9%28.1%25.9%28.9%25.7%26.5%26.4%28.3%25.2%58.7%
Net Profit42477245515063485021243
EPS in Rs2.93.244.963.073.473.314.323.323.381.381.650.28

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
13%
5 Years
15%
3 Years
14%
TTM
10%
Compounded Profit Growth
10 Years
26%
5 Years
1%
3 Years
−8%
TTM
−48%
Stock Price CAGR
10 Years
28%
5 Years
11%
3 Years
−7%
TTM
—
Return on Equity
10 Years
22%
5 Years
20%
3 Years
17%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
25.43%
−0.28 pts in a year
FIIs
4.86%
−0.41 pts in a year
DIIs
15.32%
+1.23 pts in a year
Public
38.21%
−0.56 pts in a year
Others
16.18%
0 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 45.7xEPS (12 months) ₹ 7.50Median P/E 26.6x
P/E (times)EPS (₹)

Prices are delayed and for information only. Nothing on this page is investment advice.